Register or Sign in to Save this opportunity, or Send an Inquiry.
Development of Therapeutic and Diagnostic Applications Using Ultrastable Supramolecular Interactions Between Cucurbiturils and Their Binding Partners_POSTECH
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Development of Therapeutic and Diagnostic Applications Using Ultrastable Supramolecular Interactions between Cucurbiturils and Their Binding Partners
Send an Inquiry

Key Technology Highlights



? Anticancer agent comprising Cucurbituril and pharmaceutical compound

The pharmaceutical composition can prevent effective components from being biologically degraded in vivo and can exhibit continuous drug effect for a long time just by a single dosage by controlling the release time of the platinum complex once it reaches target tumor cells.


? Cucurbituril-based Drug-delivery vehicles

Liposomes, capsules, or nanoparticles based on functionalized CB[n] can be easily prepared and decorated with imaging or targeting agents using supramolecular interaction between CB[n] and the binding partners. These vehicles can deliver various drugs with high efficiency in target-specific manner.


? Platforms for detection, immobilization, or purification of biomolecules

Highly selective and ultrastable supramolecular interaction between CB[n] and their binding partners make it possible to detect, immobilize, or purify biomolecules such as proteins or nucleic acids.


Technology Overview

n Technology Platform

The core technology of Postech is to provide cucurbit[n]uril (CB[n], n=5-10) and functionalized CB[n] with excellent quality and applied it in various fields.


n Background and unmet needs

Cucurbit[n]uril (CB[n], n = 5-10) is a family of macrocyclic compounds comprising n glycoluril units. The pumpkin-shaped CB molecules have a hydrophobic cavity and two identical carbonyl-laced portals. While the hydrophobic interior provides a potential inclusion site for nonpolar molecules, the polar ureido carbonyl groups at the portals allow CB[n] to bind ions and molecules through charge-dipole and hydrogen bonding interactions. We and others recently reported that CB[7] binds ferrocene derivatives with an exceptionally high binding constant (K ~ 1015 M-1) and good specificity in aqueous solution. The unique structure and recognition properties make CB[n] attractive not only as a synthetic receptor but also as a building block for the construction of supramolecular architectures. Furthermore, a direct functionalization method of CB[n] allowed synthesizing a wide variety of tailor-made CB derivatives to study many applications. Ion channels, vesicles, polymers, nanomaterials, ion selective electrodes incorporating CB[n], and CB-immobilized solid surfaces and silica gel have been reported and numerous other applications are being explored.

n Discovery and Achievements

Our research on CB[n] has many useful applications. For example, CB[n] can encapsulate a number of platinum-containing anticancer drugs, thus increasing their bioavailability and reducing their side effects. Nanometer-sized vesicles (JACS 2005), capsules (ACIE 2007), and nanoparticles (ChemComm 2009) made of CB[6] derivatives are potentially useful in delivering drugs to specific targeted cells and tissues to enhance the efficacy of  the drugs while minimizing the side effects. The synthetic ligand-receptor pair with ultrahigh binding affinity (PNAS 2007) which can be used as a “glue” in many chemical and biological applications may contribute to accurate and fast diagnosis. CB[n] and their derivatives to be useful in waste water treatment, odor removal, release of fragrance, separation of important bioactive molecules and many other nano- and biotechnological areas.

Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833